Capital Advisors Ltd
TSHA icon

Capital Advisors Ltd’s Taysha Gene Therapies TSHA Stock Holding History

Capital Advisors Ltd’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$0 Hold
79
– – ﹤0.01% 1648
2026
Q2 		$1K Hold
79
– – ﹤0.01% 1312
2026
Q1 		$0 Buy
79
+2
+3% +$9 ﹤0.01% 1602
2025
Q4 		$12K Sell
77
-2
-3% -$10 ﹤0.01% 774
2025
Q3 		$0 Hold
79
– – ﹤0.01% 1555
2025
Q2 		$0 Hold
79
– – ﹤0.01% 1628
2025
Q1 		$0 Hold
79
– – ﹤0.01% 1580
2024
Q4 		$0 Hold
79
– – ﹤0.01% 1581
2024
Q3 		$0 Hold
79
– – ﹤0.01% 1610
2024
Q2 		$0 Hold
79
– – ﹤0.01% 1639
2024
Q1 		$0 Hold
79
– – ﹤0.01% 1550
2023
Q4 		$0 Hold
79
– – ﹤0.01% 1489
2023
Q3 		$0 Buy
+79
New +$148 ﹤0.01% 1478

Other funds holding TSHA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Quantum Private Wealth
Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Capital Advisors Ltd's TSHA Position: Q3 2026 in Review

Capital Advisors Ltd held its Taysha Gene Therapies (TSHA) position steady in Q3 2026 at 79 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

Capital Advisors Ltd first reported a position in TSHA in Q3 2023 and has held it in 13 quarters since. The position peaked at $12K in Q4 2025. 64 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Capital Advisors Ltd held 79 shares of Taysha Gene Therapies worth $0 as of Q3 2026.
  • Capital Advisors Ltd left its Taysha Gene Therapies share count unchanged in Q3 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q3 2026, its #1648 holding.
  • Capital Advisors Ltd first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 13 quarters since.
  • Capital Advisors Ltd's Taysha Gene Therapies position peaked at $12K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Capital Advisors Ltd's 13F filing for Q3 2026, filed 27 Oct 2026.